Joint Position Statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on Routine Testing for Latent Tuberculosis Infection Prior To and During Treatment of Psoriasis Patients with IL-17 or IL-23 Inhibitors

By afschroeder • November 20, 2025

Blauvelt A, Strober BE, Eakin GS, McCormick Howard L, Langan C, van de Kerkhof PCM, Puig L, Lebwohl MG, Romiti R, Armstrong AW, Choon SE, Ramessur R, Gelfand JM, Merola JF, Winthrop KL, Torres T. Joint Position Statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on Routine Testing for Latent Tuberculosis Infection Prior To and During Treatment of Psoriasis Patients with IL-17 or IL-23 Inhibitors. J Am Acad Dermatol. 2025 Nov 17:S0190-9622(25)03232-3. doi: 10.1016/j.jaad.2025.11.033. Epub ahead of print. PMID: 41260526.

Tags: Dermatology, Publications

Autoimmune Bullous Diseases: Therapeutic Update

Kasperkiewicz M, van Beek N, Schmidt E. Autoimmune Bullous Diseases: Therapeutic Update. Drugs. 2026 Feb 23. doi: 10.1007/s40265-026-02292-3. Epub ahead of print. PMID: 41729378.

Systemic Corticosteroid Exposure in Patients with Atopic Dermatitis: A US Population-Based Study

Bunick CG, Vleugels RA, Lebwohl M, Armstrong AW, Grada A, Yue EX, Saranadasa M, Wegrzyn L, D'Andrea E. Systemic Corticosteroid Exposure in Patients with Atopic[...]

Onset and depth of response with abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis, including prominent head-and-neck dermatitis: A post hoc analysis of the head-to-head phase 3 JADE DARE study

Armstrong AW, Gooderham MJ, Eyerich K, Reich K, Blauvelt A, Hong HC, Edwards RA, Bonfanti G, Clibborn C, Biswas P, Chan G, Feeney C, Güler[...]